GRAHAM PETER J 4

What Happened

Peter J. Graham, ADC Therapeutics' Chief Legal Officer, was granted 294,800 common shares as restricted share units (RSUs) on Feb 13, 2026, valued at $3.99 per share (total value ≈ $1,176,252). On the same date, 33,294 shares were withheld by the issuer to satisfy tax withholding obligations (33,294 × $3.99 ≈ $132,843). The award is a compensation grant (transaction code A) and the withholding is reported as a tax withholding/disposition (transaction code F).

Key Details

• Transaction date: February 13, 2026; Filing date: February 18, 2026 (reporting period listed as 2026-02-13).
• Grant: 294,800 RSUs at $3.99/share — total ≈ $1,176,252.
• Tax withholding: 33,294 shares withheld at $3.99/share — total ≈ $132,843.
• Vesting: The newly granted RSUs vest one‑third on Feb 13, 2027 and one‑third on each anniversary thereafter, subject to continued service (footnote F1).
• The withheld shares relate to tax obligations for RSUs that vested (footnote F2).
• Shares owned after the transactions are not specified in the provided data.
• Transaction codes: A = award/grant; F = tax withholding/payment. Check the original Form 4 for timeliness details (Form 4s are generally due within 2 business days of the transaction).

Context

• RSU grants are a form of compensation and typically vest over time; they do not represent an immediate open‑market purchase or sale by the insider.
• The withholding of shares to cover taxes is routine and does not by itself indicate buying or selling sentiment.
• For retail investors, awards are informative about executive compensation but less directly indicative of near‑term insider conviction than open‑market purchases.